Rapid response to methylphenidate as an add-on therapy to mirtazapine in the treatment of major depressive disorder in terminally ill cancer patients: A four-week, randomized, double-blinded, placebo-controlled study

European Neuropsychopharmacology

Volumn 24, Issue 4, 2014, Pages 491-498

  Ng, Chong Guan ^a,b   Boks, Marco P M ^a,c   Roes, Kit C B ^a   Zainal, Nor Zuraida ^b   Sulaiman, Ahmad Hatim ^b   Tan, Seng Beng ^b   De Wit, Niek J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF MALAYA   (Malaysia)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cancer; Depression; Methylphenidate; Mirtazapine; Palliative; Pharmacotherapy

Indexed keywords

METHYLPHENIDATE; MIRTAZAPINE; PLACEBO; ANTIDEPRESSANT AGENT; MIANSERIN;

ADD ON THERAPY; ADULT; AGITATION; ARTICLE; BEHAVIOR DISORDER; CANCER PATIENT; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG RESPONSE; EVENING DOSAGE; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALAYSIA; MALE; MIDDLE AGED; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MORNING DOSAGE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SECONDARY ANALYSIS; SEIZURE; TERMINALLY ILL PATIENT; TREMOR; UNIVERSITY HOSPITAL; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG RESISTANCE; NEOPLASMS; PALLIATIVE THERAPY; PATIENT DROPOUT; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; BEDTIME DOSAGE; BONE CANCER; CAUSE OF DEATH; COLORECTAL CANCER; CONFUSION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DIZZINESS; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; HYPOTENSION; KIDNEY CANCER; MOOD DISORDER; OVARY CANCER; PAIN; PANCREAS CANCER; PROSTATE CANCER; SEPSIS; TERMINAL DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT CANCER; UTERINE CERVIX CANCER; VOMITING;

ACADEMIC MEDICAL CENTERS; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALAYSIA; MALE; METHYLPHENIDATE; MIANSERIN; MIDDLE AGED; NEOPLASMS; PALLIATIVE CARE; PATIENT DROPOUTS; PSYCHIATRIC STATUS RATING SCALES; TERMINALLY ILL;

EID: 84895873954     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.01.016     Document Type: Article

References (40)

1. Aishvarya S., Maniam T., Sidi H., Oei T.P. Suicide ideation and intent in Malaysia: a review of the literature. Compr. Psychiatry 2013, (Epub ahead of print). 10.1016/j.comppsych.2013.01.005.
2. Bader G.M., Hawley J.M., Short D.D. Venlafaxine augmentation with methylphenidate for treatment-refractory depression: a case report. J. Clin. Psychopharmacol. 1998, 18(3):255-256.
3. Buhagiar K., Cassar J. Methylphenidate augmentation of fluvoxamine for treatment-resistant depression: a case report and review literature. Turk. Psikiyatr. Derg. 2007, 18(2):179-183.
4. Carlson G., Kelly K. Stimulant rebound: how common is it and what does it mean. J. Child Adolesc. Psychopharmacol. 2003, 13:137-142.
5. Challman T.D., Lipsky J.J. Methylphenidate: its pharmagology and uses. Majo. Clin. Proc. 2000, 75:711-721.
6. Cochinov H.M. Depression in cancer patients. Lancet 2001, 2:499-505.
7. Cox D.J., Moore M., Burket R., Merkel R.L., Mikami A.Y., Kovatchev B. Rebound effects with long-acting amphetamine or methylphenidate stimulant medication preparations among adolescent male drivers with attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 2008, 18:1-10.
8. Fantino B., Moore N. The self-reported montgomery-asberg depression rating scale is a useful evaluated tool in major depressive disorder. BMC Psychiatry 2009, 9:26.
9. Fernandez F., Adams F. Methylphenidate treatment of patients with head and neck cancer. Head Neck Surg. 1986, 8:296-300.
10. Fernandez F., Adams F., Holmes V.F., Levy J.K., Ncidhart M. Methylphenidate for depressive disorders in cancer patients: an alternative to standard antidepressants. Psychosomatics 1987, 28:455-461.
11. Guy, 1976. ECDEU assessment manual for psychopharmacology, US Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration, Rockville, MD.
12. Hardy S.E. Methylphenidate for treatment of depressive symptoms, apathy, and fatigue in medically ill older adults and terminally ill adults. Am. J. Geriatr. Pharmacother. 2009, 7(1):34-59.
13. Homsi J., Nelson K.A., Sarhill N., Rybicki L., LeGrand S.B., Davis M.P., Walsh D. A phase II study of methylphenidate for depression in advanced cancer. Am. J. Hosp. Palliat. Med. 2001, 18:403-407.
14. Homsi J., Walsh D., Nelson K.A., LeGrand S., Davis M. Methylphenidate for depression in hospice practice: a case series. Am. J. Hosp. Palliat. Care 2000, 17(6):393-398.
15. Huffman J.C., Stern T.A. Using psychostimulants to treat depression in the medically Ill. Prim. Care Companion J. Clin. Psychiatry 2004, 6(1):44-46.
16. Kadan-Lottick N.S., Vanderwerker L.C., Block S.D., Zhang B., Prigerson H.G. Psychiatric disorders and mental health service use in patients with advanced cancer. A report from the coping with cancer study. Cancer 2005, 104:2872-2881.
17. Kaminski M., Sjogren P. The use of psychostimulants in palliative and supportive treatment of cancer patients. Adv. Palliat. Med. 2007, 6:23-31.
18. Kraemer M., Uekermann J., Wiltfang J., Kis B. Methylphenidate-Induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature. Clin. Neuropharmacol. 2010, 33(4):204-206.
19. Lavretsky H., Park S., Siddarth P., Kumar A., Reynolds C.F. Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial. Am. J. Geriatr. Psychiatry 2006, 14(2):181-185.
20. Lee H.M., Gill J.S., Pillai S.K., Ng C.G. Rapid improvement in medically ill elderly patients treated with methylphenidate for apathy. Afr. J. Pharm. Pharmacol. 2012, 6(8):505-507.
21. Macleod A.D. Methylphenidate in terminal depression. J. Pain Symptom Manage. 1998, 16:193-198.
22. Maniam T., Sidi H., Razali R. Perspectives in Malaysian psychiatry. Asia. Pac. Psychiatry 2013, 5(Suppl 1):S2-S3.
23. Masand P.S., Tesar G.E. Use of stimulants in the medically ill. Psychiatry 1995, 52:456-463.
24. Massie M.J., Popkin M.K. Depressive disorders. Psycho-oncology 1998, 518-519. Oxford University Press, NY. J.C. Holland (Ed.).
25. Minton O., Richardson A., Sharpe M., Hotopf M., Stone P.C. Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis. J. Pain Symptom Manage. 2011, 41(4):761-767.
26. Miovic M., Block S. Psychiatric disorders in advanced cancer. Cancer 2007, 110:1665-1676.
27. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979, 134:382-389.
28. Ng C.G., Boks M.P., Zainal N.Z., de Wit N.J. The prevalence and pharmacotherapy of depression in cancer patients. J. Affect Disord. 2011, 131(1-3):1-7.
29. Nik Jaafar N.R., Selamat Din S.H., Mohamed Saini S., Ahmad S.N., Midin M., Sidi H., Silim U.A., Baharudin A. Clinical depression while caring for loved ones with breast cancer. Compr. Psychiatry 2013, (Epub ahead of print). 10.1016/j.comppsych.2013.03.003.
30. O'Keefe D.J. Posthoc power, observed power, a priori power, retrospective power, prospective power, achieved power: sorting out appropriate uses of statistical analyses. Commun. Methods Meas. 2007, 1(4):291-299.
31. Olin J., Masand P. Psychostimulants for depression in hospitalized cancer patients. Psychosomatics 1996, 37:57-62.
32. Pinheiro J., Bates D., DebRoy S., Sarkar D., The R Development Core Team, 2012. nlme: Linear and Nonlinear Mixed Effects Models. R package version 3.1-105.
33. Riechelmann R.P., Burman D., Tannock I.F., Rodin G., Zimmermann C. Phase II trial of mirtazapine for cancer-related cachexia and anorexia. Am. J. Hosp. Palliat. Care 2010, 27:106-110.
34. Rodin G., Lloyd N., Katz M., Green E., Mackay J.A., Wong R.K. Supportive care guidelines group of cancer care ontario program in evidence-based care. The treatment of depression in cancer patients: a systematic review. Support Care Cancer 2007, 15:123-136.
35. Rozans M., Dreisbach A., Lertora J.J.L., Kahn M.J. Palliative uses of methylphenidate in patients with cancer: a review. J. Clin. Oncol. 2002, 20:335-339.
36. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The mini-international neuropsychiatric interview (m.i.n.i.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin Psychiatry 1998, 59(Suppl 20):S22-S33.
37. Tan M., Appleton R. Attention deficit and hyperactivity disorder, methylphenidate, and epilepsy. Arch. Dis. Child. 2005, 90(1):57-59. 10.1136/adc.2003.048504.
38. Tan S.B., Ng C.G., Lim K.S., Subramaniam P., Moy F.M., Lim E.J., Loh E.C., Lam C.L., 2012. The experiences of suffering of palliative care patients in malaysia: a thematic analysis. Am. J. Hosp. Palliat. Care. http://dx.doi.org/10.1177/1049909112458721.
39. Wallace A.E., Kofoed L.L., West A.N. Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients. Am. J. Psychiatry 1995, 152:929-931.
40. Wilkinson E.K. Problems of conducting research in palliative care. Providing a Palliative Care Service: Towards an Evidence Base 1999, 22-29. Oxford University Press, New York. N. Bosanquet, C. Salisbury (Eds.).